Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer
June 24th 2020Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.